Zoledronic Acid Prevents Bone Loss in Premenopausal Women Undergoing Adjuvant Chemotherapy for Early-Stage Breast Cancer
Open Access
- 10 October 2008
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (29), 4739-4745
- https://doi.org/10.1200/jco.2008.16.4707
Abstract
Purpose Adjuvant chemotherapy for breast cancer (BC) may be associated with increased rates of bone loss and decreased bone mineral density (BMD) and may lead to premature osteoporosis and increased fracture risk. We examined whether zoledronic acid (ZA) prevents bone loss in premenopausal women receiving chemotherapy for early-stage BC. Patients and Methods This study is a randomized, double-blind, multicenter, phase III trial comparing ZA (4 mg intravenously every 3 months) versus placebo for 1 year. Premenopausal women underwent serial BMD measurements before initiating chemotherapy and at 6 and 12 months. The primary outcome was percent change in lumbar spine (LS) BMD at 6 months. Secondary outcomes were percent change at any BMD site and markers of bone turnover at 12 months. Linear mixed model analysis for repeated measures was performed. Results Of 101 women who were randomly assigned and completed baseline evaluation, 96 completed the 6-month evaluation, and 85 completed the 12-month evaluation. Baseline characteristics were comparable between the groups. Mean age was 42 years. Placebo was associated with significant decline in LS BMD at both 6 (2.4%) and 12 (4.1%) months. Similarly, total hip BMD declined by 0.8% at 6 months and 2.6% at 12 months. In contrast, BMD remained stable in ZA patients (P < .0001 compared with placebo). Conclusion Premenopausal women receiving chemotherapy for BC sustained significant bone loss at the LS and hip, whereas BMD remained stable in women who received ZA. Administration of ZA during the first year of chemotherapy is an effective and well-tolerated strategy for preventing bone loss.Keywords
This publication has 28 references indexed in Scilit:
- Bone Density in Breast Cancer: When to Intervene?Journal of Clinical Oncology, 2007
- Once-Yearly Zoledronic Acid for Treatment of Postmenopausal OsteoporosisNew England Journal of Medicine, 2007
- Zoledronic Acid Prevents Cancer Treatment–Induced Bone Loss in Premenopausal Women Receiving Adjuvant Endocrine Therapy for Hormone-Responsive Breast Cancer: A Report From the Austrian Breast and Colorectal Cancer Study GroupJournal of Clinical Oncology, 2007
- Skeletal Sites for Osteoporosis Diagnosis: The 2005 ISCD Official PositionsJournal of Clinical Densitometry, 2006
- Annual Report to the Nation on the Status of Cancer, 1975–2002, Featuring Population-Based Trends in Cancer TreatmentJNCI Journal of the National Cancer Institute, 2005
- Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17JNCI Journal of the National Cancer Institute, 2005
- Comparison of a Single Infusion of Zoledronic Acid with Risedronate for Paget's DiseaseNew England Journal of Medicine, 2005
- Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective studyJournal of Bone and Mineral Research, 1996
- Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Synopsis of a WHO reportOsteoporosis International, 1994
- Age and bone mass as predictors of fracture in a prospective study.JCI Insight, 1988